Information for healthcare professionals
Ozempic®. For adults with type 2 diabetes to improve glycemic control, when diet and exercise plus maximal tolerated metformin dose alone do not achieve adequate glycemic control.
Information for healthcare professionals
Ozempic®. For adults with type 2 diabetes to improve glycemic control, when diet and exercise plus maximal tolerated metformin dose alone do not achieve adequate glycemic control.
Watch this short video to learn more about Ozempic®
Chat with an eRepAsk a medical questionStay up to dateGet the latest Ozempic® newsOur Ozempic® Patient Support Program is designed to help your patients at every stage of their treatment journey, as a compassionate, empathetic, and non-judgmental companion.
The program is designed to be multifaceted, helping your patients with motivation, goal setting, coping strategies, side effect management, emotional support, nutrition and the development of new routines and habits. It supports multiple learning styles through both coaching and peer learning opportunities provided via videos, infographics, guided tours, tips and tricks, and practical planning tools.
As part of this support program, your patients can download the Ozempic® app from Apple’s App Store or Google Play. The Ozempic® app is a support tool to help your patients get started and stay motivated and features Sema, a personal virtual companion. Sema can help your patients set regular dose reminders, schedule and prepare for appointments, track doses, track lifestyle changes and more. And Sema can generate PDF summaries for you to review as you help your patients along their treatment journey.
We’re pleased to announce that innoviCares will now cover a portion of the cost* of Ozempic®. InnoviCares is a free payment assistance card that helps Canadians save money on select prescription medications and healthcare products. This payment assistance is sponsored by Novo Nordisk and is available to patients in all provinces and territories except Québec.
How do you help your patients benefit from innoviCares? Provide your patients with an innoviCares card or tear sheet and tell them to present the card and prescription when asking for the brand at pharmacy. Payment is automatic and coordinates seamlessly with your patients’ existing drug plans. Patients can also get a free card by visiting the innoviCares website.
*Depending on the benefit type and patient’s existing coverage, the card will pay all or some of the MLP, U&C mark up and/or dispensing fee. The innoviCares card is designed to provide the user with specific offerings. The user may still be responsible for additional costs not covered by their innoviCares card. Availability varies by province and territory. Individual programs may change or end at the manufacturer’s discretion.We’re replacing the Ozempic® 2-pack that contains the two pens with 2 mg each (total of 4 mg/3 mL) with a 1-pack containing one pen of. It’s the same quantity of Ozempic®, just in one pen rather than two.
The SUSTAIN 7 trial was an open-label, parallel-group, phase 3b trial done at 194 hospitals, clinical institutions or private practices in 16 countries. Eligible patients were aged 18 years or older and had type 2 diabetes with A1C 7.0–10.5% (53.0–91.0 mmol/mol) on metformin monotherapy. Patients were randomly assigned (1:1:1:1) by use of an interactive web-response system to once-a-week treatment with either Ozempic® 0.5 mg, Trulicity® 0.75 mg, Ozempic® 1 mg, or Trulicity® 1.5 mg subcutaneously. The primary endpoint was change from baseline in percentage A1C; the confirmatory secondary endpoint was change in bodyweight, both at week 40. The trial was powered for A1C non-inferiority (margin 0.4%) and bodyweight superiority.2
At week 40, patients on Ozempic® 1 mg once weekly as an add-on to metformin experienced:
1.6% reduction in A1C from baseline (n=300, baseline 8.2%)1,2
5.8 kg weight loss from baseline (baseline 95.5 kg)1,2 (Ozempic® is not indicated for weight loss)
Demonstrated superior A1C reduction vs. Trulicity®, both as add-ons to metformin (p<0.0001)
At 40 weeks, patients on Ozempic® 0.5 mg once weekly saw a 1.4% reduction in A1C (n=301, baseline 8.3%) and patients on Ozempic® 1 mg once weekly experienced a 1.6% A1C reduction (n=300, baseline 8.2%) compared with patients on Trulicity® 0.75 mg who saw a 1.1% reduction (n=299, baseline 8.2%) and those on Trulicity® 1.5 mg who saw a 1.3% reduction (n=299, baseline 8.2%). Both Ozempic® 0.5 mg and Ozempic® 1 mg showed statistically significant reductions versus Trulicity® 0.75 mg and 1.5 mg, respectively (p<0.0001).1,2
Patients who achieved A1C of <7%
At 40 weeks, 65% of patients on Ozempic® 0.5 mg and 73% of patients on Ozempic® 1 mg once weekly achieved an A1C of <7.0%. 51% of patients on Trulicity® 0.75 mg and 63% on Trulicity® 1.5 mg achieved an A1C of <7.0%.1,2
Demonstrated weight reduction vs. Trulicity®, both as add-ons to metformin (2° endpoint, p<0.0001)
At 40 weeks, patients on Ozempic® 0.5 mg once weekly demonstrated weight loss of 4.2 kg (baseline 96.4 kg) while patients on Ozempic® 1 mg demonstrated weight loss of 5.8 kg (baseline 95.5 kg). Patients on Trulicity® 0.75 mg demonstrated weight loss of 2.1 kg (baseline 95.6 kg) while those on Trulicity® 1.5 mg demonstrated weight loss of 2.8 kg (baseline 93.4 kg). Ozempic® showed more than 2x the weight change versus Trulicity®, both as add-ons to metformin.1,2 (Ozempic® is not indicated for weight reduction.)
The SUSTAIN 2 trial was a 56-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial in which 1,231 patients were randomized 2:2:1:1 to Ozempic® 0.5 mg/Januvia® placebo, Ozempic® 1 mg/Januvia® placebo, Januvia®/Ozempic® 0.5 mg placebo or Januvia®/Ozempic® 1 mg placebo, all in combination with metformin (94%) and/or TZD (6%). Subjects continued pre-trial background medication throughout the entire trial. The primary objective was to compare the effect of once weekly dosing of 2 dose levels of Ozempic® vs. Januvia® 100 mg once daily on glycemic control after 56 weeks of treatment.
Demonstrated A1C reductions
At 56 weeks, patients on Ozempic® 0.5 mg once weekly saw a 1.3% reduction in A1C and those on Ozempic® 1 mg once weekly experienced a 1.5% reduction (both groups n=409, baseline 8.0%; p<0.0001) compared with patients on Januvia® 100 mg who saw a 0.7% reduction (n=407, baseline 8.2%). Both Ozempic® 0.5 mg and Ozempic® 1 mg showed statistically significant reductions versus Januvia®.1
Patients who achieved A1C of <7%
At 56 weeks, 66% of patients on Ozempic® 0.5 mg and 73% of patients on Ozempic® 1 mg once weekly achieved an A1C of <7.0%. 40% of patients on Januvia® 100 mg achieved an A1C of <7.0%.1
Demonstrated weight change
Patients on Ozempic® 0.5 mg once weekly demonstrated weight change of -4.2 kg (baseline 89.9 kg) while patients on Ozempic® 1 mg demonstrated weight change of -5.5 kg (baseline 89.2 kg). Patients on Januvia® 100 mg demonstrated weight change of -1.7 kg (baseline 89.3 kg).1 (Ozempic® is not indicated for weight reduction).
In one large study looking at cardiovascular safety with Ozempic®, there was no increased risk for time to first major adverse cardiovascular event (MACE; components of MACE are cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction) versus placebo.1
The SUSTAIN 6 trial was a 104-week, double-blind trial in which 3,297 patients with type 2 diabetes and high risk of cardiovascular events were randomized to Ozempic® 0.5 mg once weekly, Ozempic® 1 mg once weekly, or placebo in addition to standard of care. The primary objective of the trial was to confirm that treatment with Ozempic® does not result in any unacceptable increase in cardiovascular risk as compared to placebo in adults with type 2 diabetes. This was done by demonstrating that the upper limit of the two-sided 95% confidence interval (CI) of the hazard ratio for Ozempic® versus placebo is less than 1.8 when comparing time to first occurrence of a major adverse cardiovascular event.
There was no increased risk for MACE observed with Ozempic®. The estimated hazard ratio of MACE associated with Ozempic® relative to placebo was 0.74 with a 95% confidence interval of 0.58-0.95.1
Consider Ozempic® as an option for your type 2 diabetes patients.†
Ozempic® is indicated for the once weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:1
Learn more about what Ozempic® can do for your patients in future articles.
† Comparative clinical significance has not been established.
© 2019 Novo Nordisk Canada Inc.
All trademarks and registered trademarks are the property of their respective owners.
Ozempic® is a registered trademark of Novo Nordisk A/S and used under licence by Novo Nordisk Canada Inc. Januvia® is a registered trademark of Merck Canada Inc. Novo Nordisk Canada Inc.,
Tel: (905) 629-4222 or 1-800-465-4334. www.novonordisk.ca
